In the same tables, values within parentheses represent the percentage Cabozantinib ic50 of differences compared with baseline. This was computed as (x0 − x)/x0 × 100%, where x0 is the initial value (at inclusion) and x the actual value (after 30 and 60 d, respectively). Owing to the number of subjects (29) in each group, we chose t repartition, which requires a near-gaussian distribution

of data and similar standard deviations in the compared groups. Before the statistical analysis, variables were examined for normal distribution as determined by the Kolmogorov–Smirnov and Shapiro–Wilk tests. To verify the similarity of dispersions, the Levene test was used. For biochemical analyses, blood samples of fasting venous blood were taken in the morning Silmitasertib and after 30 d and then 60 d of treatment. Commercial tubes were used

to collect the blood for biochemical parameter determination. Basic biochemical parameters such as lipid profile (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and triacylglycerols) and inflammatory markers (serum high-sensitivity C-reactive protein [hs-CRP]) were analyzed in serum by standard biochemical procedures using the Cobas Integra 400 Plus automatic analyzer and kits (Roche, Switzerland). N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was determined using the Cobas h232 analyzer and tests (Roche Diagnostics GmbH, Mannheim, Germany). Secondary outcomes were the CCS angina class as assessed by a physician during the subject’s interview, the mean number of angina attacks per week, and the SAQ scores obtained at inclusion and the final PAK5 visit after 60 d. The questionnaires were completed by the subjects or

with the help of a relative or nurse. Regarding the number of angina episodes per week and nitroglycerin consumption, subjects were instructed to keep a diary with the number of angina episodes they had and the number of nitroglycerin tablets they used. The SAQ is a 19-item questionnaire intended to measure functional status in subjects with coronary artery disease [22] and [23]. Two emergency telephone numbers were given to the subjects to maintain contact during the study in case of adverse events or other concerns related to the study. Participants were instructed to inform the test supervisor if they chose to discontinue the study owing to adverse effects. There was a significant decrease of hs-CRP in all groups at the 30-d and 60-d visits (Table 2). This decrease was greater for group 3 (CF), followed by group 2 (resveratrol plus CF). After 30 d, group 3 continued to show the greatest decrease (22%), followed by groups 1 and 2 (almost insignificant). After 60 d, group 2 exceeded group 1 (30.3% versus 24.6%), but group 3 (CF) still showed the most significant decrease (39.7%). Table 2 presents the changes in NT-proBNP in all groups. NT-proBNP was significantly lowered by resveratrol (group 1, by 59.